Jun 2024 | From Ikena Oncology
IK-175, an Oral AHR Inhibitor, as Monotherapy and in Combination with Nivolumab in Patients with Urothelial Carcinoma Resistant/Refractory to PD-1/L1 Inhibitors: Final Phase 1b Results
David H. Aggen, M.D., Ph.D. | ASCO Annual Meeting 2024
Jun 2024 | From Ikena Oncology
A First In Human Study of IK-595, an Oral MEK/RAF Molecular Glue, In Patients with RAS- or RAF- Altered Advanced Solid Tumors
Nehal J. Lakhani, M.D., Ph.D. | ASCO Annual Meeting 2024
Apr 2024 | From Ikena Oncology
IK-595, a best-in-class MEK-RAF molecular glue, drives broad and potent anti-tumor activity across RAS/MAPK pathway-altered cancers as a monotherapy and in combination
Eric Haines, Ph.D., M.Sc. | AACR Annual Meeting 2024
Oct 2023 | From Ikena Oncology
IK-595, a best-in-class MEK-RAF complex inhibitor, drives broad and potent anti-tumor activity in RAS/RAF-driven tumorsSource: From Ikena Oncology
Eric Haines, Ph.D., M.Sc. | EORTC-NCI-AACR 2023
Sep 2023 | From Ikena Oncology
IK-595 Targeting MEK-RAF Complex to Overcome CRAF Mediated Resistance & Drive Superior Anti-Tumor Activity in RAS/RAF Altered Cancers
Michelle Zhang, Ph.D. | 5th Annual RAS-Targeted Drug Development Summit 2023
Apr 2023 | From Ikena Oncology
IK-930, a Paralog Selective TEAD Inhibitor Effectively Attenuates Drug-Tolerant Persister Cell Proliferation
Daniel Hidalgo, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023
Apr 2023 | From Ikena Oncology
IK-930, a TEAD Paralog Selective Inhibitor for Treating YAP/TAZ-TEAD Dependent Cancers
Nathan Young, Ph.D. & Marta Sanchez-Martin, Ph.D. | AACR Annual Meeting 2023
Mar 2023 | From Ikena Oncology
IK-595, a MEK-RAF complex inhibitor, obviates CRAF mediated resistance resulting in superior RAS/MAPK pathway inhibition and anti-tumor activity in RAS/RAF altered cancers
X. Michelle Zhang, PhD | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
IK-595, A MEK/RAF Complex Inhibitor, Obviates CRAF Mediated Resistance Resulting in Superior RAS/MAPK Pathway Inhibition and Anti-tumor Activity in RAS/RAF Altered Cancers
Eric Haines | AACR Special Conference: Targeting RAS
Mar 2023 | From Ikena Oncology
The Ah Receptor from Toxicity to Therapeutics. Report from the 5th AHR Meeting at Penn State University, USA, June 2022
McGovern, K et al. | International Journal of Molecular Sciences